Skip to main content
. Author manuscript; available in PMC: 2021 Aug 3.
Published in final edited form as: Oncogene. 2009 Nov 23;29(7):966–977. doi: 10.1038/onc.2009.405
Oct4 (169bp) Forward: 5′-CTTGCTGCAGAAGTGGGTGGAGGAA-3′
Reverse: 5′ -CTGCAGTGTGGGTTTCGGGCA-3′
GATA4 (194bp) Forward: 5′-TCCCTCTTCCCTCCTCAAATTC-3′
Reverse: 5′ -TCAGCGTGTAAAGGCATCTG-3′
Flk1 (400 bp) Forward: 5′-CATATCTGTCCTGATGTGATATGTC-3′
Reverse: 5′ -CATAGCATGTCTTATAGTCATTGTTC-3′
HBE1 (126 bp) Forward: 5′-TGCATGTGGATCCTGAGAAC-3′
Reverse: 5′ -CGACAGCAGACACCAGCTT-3′
Pax6 (317 bp) Forward: 5′-ACCCATTATCCA-GATGTGTTTGCCCGAG-3′
Reverse: 5′ -ATGGTGAAGCTGGGCATAGGCGGCAG-3′
T (274 bp) Forward: 5′-GCCCTCTCCCTCCCCTCCACGCACAG-3′
Reverse: 5′ -CGGCGCCGTTGCTCACAGACCACAGG-3′
E-cadherin (129 bp) Forward: 5′-CCTGGTTCAGATCAAATCCAAC-3′
Reverse: 5′ -GTCACCTTCAGCCATCCTG-3′
β-Actin (401 bp) Forward: 5′-ACAGCAGTCGGTTGGAGCGAGCATC-3′
Reverse: 5′ -CAAGTCAGTGTACAGGTAAGCCCTG-3′
Nodal (126 bp) Forward: 5′-ACCGAGTCCCTTCCACTTGTTG-3′
reverse: 5′-AGAGGCACCCACATTCTTCCAC-3′